HONG KONG AND SHANGHAI, CHINA, FLORHAM PARK, N.J., April 5, 2024 (Globe Newswire) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announced a new Published data and updated data. Results from research on several of HatchMed's discovered compounds will be presented at the next American Association for Cancer Research (“AACR”) Annual Meeting 2024, to be held in San Diego, California, April 5-10, 2024. It will be announced.
Early preclinical data HMPL-506, Novel, highly potent and differentiated menin MLL inhibitors For the treatment of certain types of acute leukemia. Compared to other her five menin inhibitors in clinical development, HMPL-506 MLL-Relocated, NPM1 Mutant leukemia cell line model. Additionally, combining HMPL-506 with azacitidine, venetoclax, or gilteritinib synergistically improved antitumor efficacy. MLL– Both rearranged leukemias in vitro and in vivo. The investigational drug candidate demonstrated a favorable pharmacokinetic profile, high selectivity, and low risk of cardiotoxicity. A Phase I study of HMPL-506 is scheduled for the second half of 2024.
Early preclinical data are also presented. HMPL-A067 (HMA800067), a novel antibody-drug conjugate targeting CD38 (ADC), daratumumab was conjugated with the cytotoxic payload monomethyl auristatin E (MMAE) via a novel linker. It showed significantly better antitumor activity than daratumumab, including in several B-cell malignancy models that were resistant to daratumumab treatment.
Additional presentations include preclinical data on ERK 1/2 inhibitors. HMPL-295early clinical data on Syk inhibitors; sobreprenib, in patients with lymphoma. Additional clinical data from global studies of VEGFR inhibitors, fruquintinibMET inhibitor, savolitinibseveral investigator-initiated studies on fruquintinib and VEGFR/CSF-1R/FGFR inhibitors; Sulfatinib.
Details of the lecture content are as follows.
summary title | Presenter / Lead author | Presentation details |
sponsored research | ||
HMPL-506 is a novel, highly potent and differentiated menin MLL inhibitor for the treatment of disease. MLL relocation and NPM1Mutant acute leukemia in preclinical models | Min Cheng, HatchMed, Shanghai, China | #2113 Poster session (PO.ET07.02 – Pharmacodynamic biomarkers of drug response) Monday, April 8, 2024 |
HMPL-A067 (HMA800067), a novel CD38-targeted antibody-drug conjugate (ADC), demonstrated superior antitumor activity to daratumumab in a preclinical B-cell malignancy model | Yan Xu, HatchMed, Shanghai, China | #1890 Poster session (PO.ET01.02 – Antibody-drug conjugates and bispecific antibodies) Monday, April 8, 2024 |
Preclinical characterization of HMPL-295, a potent and selective ERK1/2 inhibitor | Jia Hu, HatchMed, Shanghai, China | #1661 Poster Session (PO.MCB03.01 – Cell Signaling Components as Therapeutic Targets) Monday, April 8, 2024 |
Targeting YAP1/TEAD signaling resensitizes MAPK/ERK pathway inhibitors in KRAS-driven cancer cells | Xianwen Yang, HatchMed, Shanghai, China | #1931 Poster Session (PO.ET03.04 – Drug Resistance 2: Ras GTPase) Monday, April 8, 2024 |
Safety and efficacy of the Syk inhibitor sobreprenib (HMPL-523) in patients with relapsed or refractory lymphoma | Paolo Strati, University of Texas MD Anderson Cancer Center, USA | #CT144 Poster Session (PO.CT01.03 – Phase 0 and Phase I Clinical Trials) Monday, April 8, 2024 |
Early carcinoembryonic antigen (CEA) kinetics to predict efficacy of fruquintinib (F) + best supportive care (BSC) in metastatic colorectal cancer (mCRC) patients enrolled in FRESCO-2 | Stefano Lonardi, Veneto Oncology Institute IOV-IRCCS, Padua, Italy | #6408 Poster Session (PO.CL01.10 – Predictive Biomarkers 5) Tuesday, April 9, 2024 |
savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in EGFR-mutated (EGFRm), MET-amplified advanced NSCLC patients (pts) who progressed on OSI | James Chih-Hsin Yang, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan. | #CT251 Poster Session (PO.CL01.10 – Predictive Biomarkers 5) Tuesday, April 9, 2024 |
Researcher-led research | ||
Enhancement of anticancer effects through ROS-dependent ferroptosis: synergistic effect of sulfatinib and cisplatin in small cell lung cancer | Xiaolin Li, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. | #2122 Poster session (PO.ET07.02 – Pharmacodynamic biomarkers of drug response) Monday, April 8, 2024 |
Efficacy of sulfatinib in non-small cell lung cancer treatment and its underlying mechanism | Yanfang Zheng, Affiliated Cancer Hospital and Research Institute of Guangzhou Medical University, Guangzhou, China | #2126 Poster session (PO.ET07.02 – Pharmacodynamic biomarkers of drug response) Monday, April 8, 2024 |
Enhanced radiosensitivity in biliary tract cancer: dual role of sulfatinib in tumor suppression and macrophage reprogramming | Hong Ma, Wuhan Union Hospital, Wuhan, China | #2127 Poster session (PO.ET07.02 – Pharmacodynamic biomarkers of drug response) Monday, April 8, 2024 |
Sulfatinib treatment in pancreatic cancer: elucidating the role of GPR34 in TAM and increasing the efficacy of immunotherapy | Jihui Hao/Song Gao, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China | #2128 Poster session (PO.ET07.02 – Pharmacodynamic biomarkers of drug response) Monday, April 8, 2024 |
Efficacy and underlying mechanisms of sulfatinib in combination with PD-1 monoclonal antibody and chemotherapy in pancreatic cancer | Guanghai Dai/Ru Jia, Chinese People's Liberation Army General Hospital (CPLAGH), Beijing, China | #2129 Poster session (PO.ET07.02 – Pharmacodynamic biomarkers of drug response) Monday, April 8, 2024 |
Optimizing the treatment schedule of radiotherapy in combination with VEGFR-TKI and PD-(L)1 inhibitors in metastatic colorectal cancer | Tao Zhang/Zhenyu Lin, Cancer Center, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, China | #3827 Poster Session (PO.CL10.04 – Exploring Results Using Real-World Data) Monday, April 8, 2024 |
Clinical and epidemiological profile of neuroendocrine differentiation – a hospital-based retrospective study | Susheng Shi/Yaru Wen, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China | #4630 Poster Session (PO.ET06.04 – Molecular Classification of Tumors for Diagnosis, Prognosis, and Treatment Outcomes) Tuesday, April 9, 2024 |
Epidemiological characteristics and treatment strategies of neuroendocrine differentiated gastric cancer (NED) | Jun Zhang, First Affiliated Hospital of Chongqing Medical University, Chongqing, China. | #4864 Poster Session (PO.PS01.08 – Descriptive Epidemiology and Statistical Epidemiology Methodology) Tuesday, April 9, 2024 |
Initial efficacy of sulfatinib plus sintilimab and IBI310 in patients with high-grade progressive neuroendocrine tumors: a multicenter, single-arm, phase 2 study | Lin Shen/Ming Lu, Peking University Cancer Hospital and Research Institute, Beijing, China | #CT266 Poster session (PO.CT02.02 – Phase II clinical trial 2) Tuesday, April 9, 2024 |
About HatchMed
HatchMed (NASDAQ/AIM:Ho Chi Minh City; HKEX:13) is an innovative commercial-stage biopharmaceutical company. We are committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immune diseases. The company employs approximately 5,000 people, with a core team of approximately 1,800 in oncology/immunology. Since its founding, HatchMed has focused on bringing cancer drug candidates discovered in-house to patients around the world, with its first three drugs sold in China and the first of these in the United States. It's on sale. For more information, please visit: Visit www.hatch-med.com or follow us on LinkedIn.
Forward-looking statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HatchMed's current expectations regarding future events. Therapeutic potential of fruquintinib, savolitinib, sulfatinib, sobreprenib, HMPL-295, HMPL-506, and HMA800067, further clinical development of fruquintinib, savolitinib, sulfatinib, sobreprenib, HMPL-295, HMPL-506, and HMA800067, fruquintinib, savolitinib, All studies of sulfatinib, sobreprenib, HMPL-295, HMPL-506, and HMA800067 have met their primary or secondary endpoints, as well as expectations regarding the timing of completion and publication of results for such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects who meet the study's inclusion and exclusion criteria. changes in clinical protocols or regulatory requirements; unexpected adverse events or safety issues; Achieving primary or secondary study endpoints and obtaining regulatory approval in various jurisdictions and subsequent Commercially acceptable ability to obtain regulatory approval. the potential market and funding sufficiency of fruquintinib, savolitinib, sulfatinib, sobreprenib, HMPL-295, HMPL-506, and HMA800067 for targeted indications; Additionally, because certain studies have relied on the use of nab-paclitaxel, sintilimab, tripalimab, pemetrexed, platinum, etoposide, or cisplatin as combination therapy, such risks and uncertainties include their safety, efficacy, and assumptions regarding availability, availability and continued regulatory approvals. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For more information on these and other risks, please refer to his HUTCHMED filings with the U.S. Securities and Exchange Commission, the Hong Kong Stock Exchange and AIM. HATCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
medical information
This press release contains information about products that may not be available in all countries or are available under different trademarks, different indications, different doses, or different strengths. Nothing contained herein should be construed as a solicitation, promotion, or advertisement for prescription drugs, including those currently in development.
contact address
Investor inquiries | +852 2121 8200 / ir@hutch-med.com |
Media inquiries | |
Ben Atwell / Alex Shaw, FTI Consulting | +44 20 3727 1030 / +44 7771 913 902 (mobile phone) / +44 7779 545 055 (mobile phone) / HUTCHMED@fticonsulting.com |
Shuyi, Brunswick | +852 9783 6894 (mobile) / HUTCHMED@brunswickgroup.com |
designated advisor | |
Athol Tweedy / Freddie Crossley / Daphne Chan, Panmure Gordon |
+44 (20) 7886 2500 |